ANTHEM
ANTHEM BIOSCIENCES LTD
ANTHEM BIOSCIENCES LTD (ANTHEM) Stock Analysis & Case Study
Is ANTHEM a good buy? The data-driven verdict.
ANTHEM BIOSCIENCES LTD (ANTHEM) trades at ₹766,on the numbers it mixed signals, a Downstox Snapshot Score of 52/100.
On the numbers, ANTHEM BIOSCIENCES LTD (ANTHEM) mixed signals, a Downstox Snapshot Score of 52/100, weighing expensive at 70.8× earnings, ROE of 22.3%. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
ANTHEM fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is ANTHEM overvalued? ANTHEM P/E vs its sector
ANTHEM's P/E of 70.8× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.26% dividend yield is below the peer median of 1.65%.
The bull case for ANTHEM
- High return on equity (22.3%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise.
- Strong ROCE (30.4%) shows the core business earns well above its cost of capital.
The bear case & risks
- A rich 70.8× P/E leaves a thin margin of safety if growth slows.
- A steep 14.1× price-to-book means most of the value is intangible/expectations, not assets on the books.
ANTHEM Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. ANTHEM scores 4/9,mixed financial health.
ANTHEM MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy ANTHEM with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 27.5% | 3.6× |
| ZerodhaCHEAPEST | 27.5% | 3.6× |
| DhanCHEAPEST | 27.5% | 3.6× |
Compare every broker on the ANTHEM MTF page.
ANTHEM vs peers,sector comparison
About ANTHEM BIOSCIENCES LTD: sector, index & market-cap context
ANTHEM BIOSCIENCES LTD (ANTHEM) is a mid-cap NSE-listed company, and a constituent of the Nifty 100 index group, with a market capitalisation of ₹43,136 Cr. See more Nifty 100 stocks.
How the ANTHEM Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of ANTHEM BIOSCIENCES LTD's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
ANTHEM analysis, FAQs
Is ANTHEM BIOSCIENCES LTD (ANTHEM) a good buy?
On the numbers, ANTHEM BIOSCIENCES LTD (ANTHEM) mixed signals, a Downstox Snapshot Score of 52/100, weighing expensive at 70.8× earnings, ROE of 22.3%. This is a data snapshot for research, not investment advice.
Is ANTHEM overvalued or undervalued?
ANTHEM trades at 70.8× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the bull case for ANTHEM?
High return on equity (22.3%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise. Strong ROCE (30.4%) shows the core business earns well above its cost of capital.
What are the risks in ANTHEM?
A rich 70.8× P/E leaves a thin margin of safety if growth slows. A steep 14.1× price-to-book means most of the value is intangible/expectations, not assets on the books.